Revisits After Discharge From Observation Up in Elderly

Share this content:
Revisits After Discharge From Observation Up in Elderly
Revisits After Discharge From Observation Up in Elderly

THURSDAY, June 22, 2017 (HealthDay News) -- For Medicare beneficiaries age 65 years and older, hospital revisits frequently occur after discharge from observation stays, and have increased over time, according to a study published online June 20 in The BMJ.

Kumar Dharmarajan, M.D., M.B.A., from the Yale University School of Medicine in New Haven, Conn., and colleagues conducted a retrospective cohort study in 4,750 U.S. hospitals. Data were included for Medicare fee-for-service beneficiaries aged 65 years or older discharged after 363,037 index observation stays, 2,540,000 index emergency department treatment-and-discharge stays, and 2,667,525 index inpatient stays during 2006 to 2011.

The researchers found that among the index observation stays, the 30-day rates of emergency department treatment-and-discharge stays, repeat observation stays, and inpatient stays were 8.4, 2.9, and 11.2 percent, respectively; the rate of any hospital revisit was 20.1 percent and death was 1.8 percent. Almost half (49.7 percent) of all revisits were for inpatient stays. From 2006 to 2011 there was an increase in revisit rates for emergency department treatment-and-discharge stays, repeat observation stays, and any hospital revisit (P < 0.001 for trend); there were no changes in 30-day rates of inpatient stays (P = 0.054) and 30-day mortality (P = 0.091).

"Hospital revisits are common after discharge from observation stays, frequently result in inpatient hospitalizations, and have increased over time among Medicare beneficiaries," the authors write.

Several authors disclosed financial ties to the pharmaceutical, medical device, and health care industries.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths